Wyeth Nycomed GmbH filed a lawsuit against a Novartis AG (NVS) unit, alleging the unit's application to sell a generic version of Wyeth's heartburn drug Protonix violates a U.S. patent for the branded drug.
Novartis' Sandoz generic unit notified the companies in early April that it filed for U.S. Food and Drug Administration approval of a generic, injectable formulation of the drug, which Wyeth markets as Protonix I.V. Wyeth, which licenses the patent from Nycomed, also sells Protonix in tablet form.
The details can be read here.
No comments:
Post a Comment